Drug Profile
PBI 1393
Alternative Names: PBI-1393Latest Information Update: 14 Oct 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Liminal BioSciences
- Class Antineoplastics
- Mechanism of Action Lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada
- 17 Jan 2011 PBI 1393 is available for licensing as of 17 Jan 2011. http://www.prometic.com/en/index.php